Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Verona Pharma Plc ADR shares valued at $4,339,000 were purchased by DAVID ZACCARDELLI on Jun 11 ’25. At $86.78 per share, DAVID ZACCARDELLI acquired 50,000 shares.
Also, MARK HAHN purchased 50,000 shares, netting a total of over 4,339,000 in proceeds.
Before that, Hahn Mark W had sold 204,864 shares from its account. In a trade valued at $1,911,668, the Chief Financial Officer traded Verona Pharma Plc ADR shares for $9.33 each. Upon closing the transaction, the insider’s holdings decreased to 204,864 shares, worth approximately $1.14 billion.
As published in their initiating research note from TD Cowen on April 28, 2025, Verona Pharma Plc ADR [VRNA] has been a Buy and the price target has been revised to $100. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of January 10, 2025, ROTH MKM has initiated its “Buy” rating for VRNA. Earlier on October 03, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for VRNA stock.
Analyzing VRNA Stock Performance
During the last five days, there has been a surge of approximately 7.23%. Over the course of the year, Verona Pharma Plc ADR shares have jumped approximately 93.91%. Shares of the company reached a 52-week high of $92.98 on 06/11/25 and a 52-week low of $43.44 on 01/10/25.
Support And Resistance Levels for Verona Pharma Plc ADR (VRNA)
According to the 24-hour chart, there is a support level at 87.44, which, if violated, would cause prices to drop to 84.83. In the upper region, resistance lies at 92.82. The next price resistance is at 95.59. RSI (Relative Strength Index) is 76.81 on the 14-day chart, showing overbought technical sentiment.
